一段话概述
Verve had a single idea: instead of taking cholesterol medication every day for life, switch off the gene that raises cholesterol, once. Its lead treatment reached patients and showed lasting reductions in LDL cholesterol. Eli Lilly bought the company in 2025 and continues the programme.
Verve Therapeutics was founded in 2018 by Sekar Kathiresan and Kiran Musunuru to apply in vivo base editing to cardiovascular disease, licensing base-editing technology from Beam Therapeutics. VERVE-102 targets PCSK9 and holds FDA Fast Track designation. Eli Lilly acquired the company in 2025 for approximately $1 billion, plus a contingent value right tied to dosing the first patient in a US Phase 3 trial.
Sources
- Eli Lilly and Company · 2025
Lilly to acquire Verve Therapeutics ↗
非投资建议
本档案为依据公开披露信息汇编的教育性资料，不构成对任何证券的买入、卖出或持有建议，也不代表对该公司前景的任何判断。生物技术领域具有高度投机性，大多数临床项目最终以失败告终。
完整免责声明 →